LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

Home・Akciju saraksts・Cogent Biosciences Inc

Cogent Biosciences Inc

Slēgts

38.33 2.4

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

37.09

Max

38.42

Galvenie mērījumi
By Trading Economics
Ienākumi	-7.4M -81M
EPS	-0.5
Darbinieki	205
EBITDA	-6.8M -79M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+47.55% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	3.4B 5.6B
Iepriekšējā atvēršanas cena	35.93
Iepriekšējā slēgšanas cena	38.33

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

4.88 / 5.87 Atbalsts un pretestība

Cogent Biosciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 18. febr. 22:31 UTC

Peļņas

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

2026. g. 18. febr. 22:18 UTC

Peļņas

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

2026. g. 18. febr. 22:11 UTC

Peļņas

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

2026. g. 18. febr. 21:52 UTC

Peļņas

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

2026. g. 18. febr. 23:56 UTC

Tirgus saruna

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

2026. g. 18. febr. 23:46 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 18. febr. 23:46 UTC

Tirgus saruna

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

2026. g. 18. febr. 23:34 UTC

Tirgus saruna

Peļņas

Brambles' Cost Control Stands Out to Bull -- Market Talk

2026. g. 18. febr. 23:33 UTC

Tirgus saruna

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

2026. g. 18. febr. 23:32 UTC

Tirgus saruna

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

2026. g. 18. febr. 22:45 UTC

Peļņas

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

2026. g. 18. febr. 22:44 UTC

Tirgus saruna

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

2026. g. 18. febr. 22:37 UTC

Peļņas

Nutrien 4Q EPS $1.18 >NTR.T

2026. g. 18. febr. 22:37 UTC

Peļņas

Nutrien 4Q Sales $5.34B >NTR.T

2026. g. 18. febr. 22:35 UTC

Peļņas

Pan American Silver 4Q EPS $1.07 >PAAS

2026. g. 18. febr. 22:35 UTC

Peļņas

Pan American Silver 4Q Rev $1.18B >PAAS

2026. g. 18. febr. 22:30 UTC

Peļņas

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

2026. g. 18. febr. 22:29 UTC

Peļņas

Kinross Gold 4Q EPS 75c >K.T

2026. g. 18. febr. 22:22 UTC

Peļņas

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

2026. g. 18. febr. 22:22 UTC

Tirgus saruna

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

2026. g. 18. febr. 22:16 UTC

Peļņas

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

2026. g. 18. febr. 22:05 UTC

Peļņas

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

2026. g. 18. febr. 22:03 UTC

Peļņas

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

2026. g. 18. febr. 22:02 UTC

Peļņas

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

2026. g. 18. febr. 22:02 UTC

Peļņas

Kaiser Aluminum 4Q Sales $929M >KALU

2026. g. 18. febr. 22:02 UTC

Peļņas

Kaiser Aluminum 4Q EPS $1.68 >KALU

2026. g. 18. febr. 22:00 UTC

Peļņas

Kinross Gold 4Q Adj EPS 67c >KGC

2026. g. 18. febr. 22:00 UTC

Peļņas

Kinross Gold 4Q Sales $2.02B >KGC

2026. g. 18. febr. 21:56 UTC

Peļņas

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

2026. g. 18. febr. 21:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Cogent Biosciences Inc Prognoze

Cenas mērķis

By TipRanks

47.55% augšup

Prognoze 12 mēnešiem

Vidējais 53.9 USD 47.55%

Augstākais 67 USD

Zemākais 45 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

11 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 11 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

4.88 / 5.87Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.